These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Energy-dependent effect of iodized contrast medium on radiation-induced chromosome aberrations. Hadnagy W; Bäuml A; Stephan G Radiat Environ Biophys; 1985; 24(1):71-4. PubMed ID: 3975352 [No Abstract] [Full Text] [Related]
45. The risk liability of nephrotropic contrast media: clinical and experimental results. Kröpelin T; Gospos C; Papacaralampous X; Freudenberg N Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():129-42. PubMed ID: 6139068 [No Abstract] [Full Text] [Related]
46. Contrast enhanced brain CT. Comparison between iohexol and metrizoate. Holtås S; Cronqvist S; Renaa T Neuroradiology; 1983; 24(4):213-5. PubMed ID: 6828237 [TBL] [Abstract][Full Text] [Related]
47. Cardiovascular side effects of various conventional, low-osmolar and non-ionic contrast media. Wink K; Wissert J Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():120-4. PubMed ID: 6139066 [No Abstract] [Full Text] [Related]
48. Oral contrast media in paediatrics. Healey T Clin Radiol; 1984 Jan; 35(1):84. PubMed ID: 6690188 [No Abstract] [Full Text] [Related]
49. [Transient hypothyroidism following administration of roentgen contrast media to the newborn and infants]. Röhner G; Rautenburg HW Med Welt; 1983 Jun; 34(23):668-70. PubMed ID: 6877078 [No Abstract] [Full Text] [Related]
50. Clinical and nephrologic tolerance of iopromide and iotrolan in computed tomography. Langer M; Langer R; Zwicker C; Speck U; Jänicke UA; Felix R Invest Radiol; 1991 Nov; 26 Suppl 1():S83-5; discussion S88-91. PubMed ID: 1808156 [No Abstract] [Full Text] [Related]
51. Tolerability of iohexol after injection into healthy volunteers. Levorstad K; Kolbenstvedt A; Kolmannskog F; Sommerfelt SC; Stormorken H; Andrew E; Sveen K Acta Radiol Diagn (Stockh); 1983; 24(3):241-51. PubMed ID: 6624528 [TBL] [Abstract][Full Text] [Related]
52. [Endomirabil, a new contrast medium for the biliary tract. Rate of adverse effects with special reference to the application time]. Barner L; Kurzen S Med Welt; 1977 Apr; 28(17):817-9. PubMed ID: 577589 [No Abstract] [Full Text] [Related]
53. Ascending lower limb phlebography: comparison of ioversol and iothalamate meglumine. Wilson AJ; Murphy WA; Destouet JM; Gilula LA; Hardy DC; Monsees B; Totty WG Can Assoc Radiol J; 1989 Jun; 40(3):142-4. PubMed ID: 2660958 [TBL] [Abstract][Full Text] [Related]
54. [A comparison of the occurrence of side-effects of ioxaglinic acid (Hexabrix) and metrizoate (Isopaque Amin) in hysterosalpingography. A randomized prospective study]. Lauridsen KN Ugeskr Laeger; 1986 May; 148(19):1141-3. PubMed ID: 3523907 [No Abstract] [Full Text] [Related]
55. Experiences with rayvist and iopromid in head and body CT. Zeitler E; Böhnlein K; Gailer H; Lindner R; Richter EI Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():162-72. PubMed ID: 6139073 [No Abstract] [Full Text] [Related]
56. A double-blind comparative study of the tolerance of sodium and meglumine ioxaglate (Hexabrix) with meglumine iothalamate (Conray) in ascending phlebography of the leg. Thomas ML; Walters HL; Briggs GM Australas Radiol; 1982 Nov; 26(3):288-90. PubMed ID: 7165617 [No Abstract] [Full Text] [Related]